We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Resmetirom: First Approval.
- Authors
Keam, Susan J.
- Abstract
Resmetirom (Rezdiffra™) is an oral thyroid hormone receptor-β (THR-β) agonist being developed by Madrigal Pharmaceuticals, Inc., to target the key underlying causes of metabolic dysfunction associated steatohepatitis (MASH) [previously known as nonalcoholic steatohepatitis (NASH)]. In March 2024, resmetirom was approved for use (under accelerated approval) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in the USA. Resmetirom is also under regulatory review in the EU for the treatment of MASH/NASH. This article summarizes the milestones in the development of resmetirom leading to this first approval for the treatment of adults with MASH/NASH.
- Subjects
METABOLIC disorders; NON-alcoholic fatty liver disease; CIRRHOSIS of the liver; ORAL drug administration; PHARMACEUTICAL industry; EUROPEAN Union; MOLECULAR structure; DRUG development; CELL receptors; GOVERNMENT regulation; ADULTS
- Publication
Drugs, 2024, Vol 84, Issue 6, p729
- ISSN
0012-6667
- Publication type
Article
- DOI
10.1007/s40265-024-02045-0